News
WADA 2027 Prohibited List: What Changes for SARMs, Peptides and PCT Drugs
WADA's 2027 Prohibited List, valid from 1 January 2027, names peptides in S0, adds SLU-PP-332, SLU-PP-915 and seladelpar as metabolic modulators, and adds imlunestrant…
All Articles
Every Sarmguide article, newest first. Pick a topic or a type to narrow the list.
News (5)
News
Enobosarm (Ostarine) Plus Wegovy: Phase 2b PLATEAU Trial Fully Enrolled, Results Due in 2027
On 27 July 2026, Veru said its Phase 2b PLATEAU trial of enobosarm (ostarine) 3 mg with semaglutide had completed enrollment of about 200…
News
FDA Advisers Back Compounding of BPC-157, TB-500, MOTS-c and Three Other Peptides (July 2026)
An FDA advisory committee voted 8–6 to back compounding of BPC-157, KPV and TB-500 and 7–5 for MOTS-c, overriding FDA staff. The vote is…
News
FDA Warning Letter: Ostarine, MK-677, Cardarine and LGD-4033 Products Are “Unapproved New Drugs” (December 2025)
In a 12 December 2025 warning letter, the FDA said products sold online as Ostarine MK-2866, MK-677, Cardarine GW501516 and LGD-4033 are unapproved new…
News
New Study Finds Ostarine Preserves Muscle on Wegovy and Ozempic
With blockbuster drugs like Wegovy and Ozempic taking over TikTok feeds and Hollywood circles, weight loss has never looked easier. These GLP-1 medications are…